Who is affected by this change?

This affects Independence Blue Cross Neurology, Pediatrics providers on Commercial plans.

When does this change take effect?

This change is effective Dec 19, 2025.

Back to dashboard

CommercialCoverageLow impact

08.01.92, Elivaldogene Autotemcel [eli-cel (Skysona®)]

Independence Blue Cross·Neurology, Pediatrics·Pharmacy

Effective date

Dec 19, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A commercial policy update for Elivaldogene Autotemcel (eli-cel/Skysona®) has been reissued, effective December 19, 2025. This appears to be a pharmacy policy update for a gene therapy treatment, though specific coverage details are not provided in the summary.

Action Required

Action needed

By December 19, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage, prior authorization requirements, or billing procedures for Elivaldogene Autotemcel (Skysona®). This gene therapy is rarely used, so impact may be minimal for most practices.

Related policy hubs

Independence Blue Cross policies Neurology Pediatrics